Compare Mesoblast Limited (MESO) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Recursion Pharmaceuticals Inc — how do they compare? Mesoblast Limited trades at $13.9 (market cap $1.80B), while Recursion Pharmaceuticals Inc trades at $3.94 (market cap $2.02B). The key difference: Mesoblast Limited and Recursion Pharmaceuticals Inc are close in size by market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| MESO | RXRX | |
|---|---|---|
Market Cap | $1.80B | $2.02B |
Volume | 225,551 | 18,610,436 |
Sector | Health | Health |
52-Week High | $20.96 | $6.79 |
52-Week Low | $13.19 | $2.84 |
Typical Hold Time | 15 Days | 22 Days |
Enterprise Value | $1.88B | $1.54B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.895, down 2.63% with bearish technical signals. The company reported substantial revenue growth to $120M in 2026 but remains unprofitable with a net margin of -47.82%. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant milestones. The stock shows mixed sentiment with 45% analyst buy ratings against bearish technical indicators.
While MESO demonstrates strong revenue growth potential and pipeline progress, persistent losses and negative profitability metrics present substantial risk. The company's cash position of $161M provides runway, but investors face volatility from clinical trial outcomes and path to profitability challenges.
RXRX trades at $3.85, up 0.39% with a bullish technical signal from moving averages. The company reported Q2 2026 EPS miss after two consecutive beats, with revenue declining from $74M in 2025 to $54M in 2026. Net losses remain substantial at -$519M, though improving from -$645M. Strategic partnerships with Tempus and Roche provide non-dilutive funding through 2028, supporting AI-driven drug discovery pipeline expansion.
High revenue multiples and persistent losses present valuation concerns, but analyst consensus leans neutral with 60% hold ratings. The stock faces execution risk in clinical development while benefiting from AI platform differentiation. Near-term catalysts include Q3 earnings and pipeline progress, though profitability remains distant.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
